Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

Br J CancerJul 8, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Katrin M Sjoquist, Alexander Dobrovic, Kristy P Robledo et al.

✦ AI-curated · Sources linked

In 30 seconds

The phase 2 EMBRACE trial evaluated olaparib in patients with platinum-sensitive relapsed high-grade serous ovarian cancer (HGSOC) and metastatic triple-negative breast cancer (TNBC) with non-germline BRCA mutations. The objective tumor response rate (OTRR) at 6 months was 40% for HGSOC and 0% for TNBC, indicating olaparib's efficacy in HGSOC but limited activity in TNBC.

Key findings

  • OTRR at 6 months was 40% for HGSOC and 0% for TNBC.
  • Promoter methylation was detected in 8/15 HGSOC and 5/7 TNBC.
  • 6-month progression-free survival was 53% for HGSOC and 17% for TNBC.
  • OTRR was 38% in methylated cases vs 43% for other HRD.

Why it matters

This study highlights the potential of olaparib in treating HGSOC with non-germline BRCA mutations, suggesting a need for further exploration of patient selection criteria to optimize treatment outcomes.

Source

PubMed · PMID 42420629Free full text on PubMed Central

Published in Br J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.